PriceTargets.com logo

Glaukos - GKOS Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $56.67
  • Forecasted Upside: 14.83%
  • Number of Analysts: 9
  • Breakdown:
  • 0 Sell Ratings
  • 4 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$49.35 As of 03/24/2023 01:00 AM ET
▲ +1.14 (2.36%)

This chart shows the closing price for GKOS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Glaukos Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GKOS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GKOS

Analyst Price Target is $56.67
▲ +14.83% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for Glaukos in the last 3 months. The average price target is $56.67, with a high forecast of $68.00 and a low forecast of $44.00. The average price target represents a 14.83% upside from the last price of $49.35.

This chart shows the closing price for GKOS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 9 polled investment analysts is to buy stock in Glaukos. This rating has held steady since June 2022, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 5 hold ratings
  • 0 sell ratings
Ratings as of
10/1/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 5 hold ratings
  • 0 sell ratings
Ratings as of
12/30/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 5 hold ratings
  • 0 sell ratings
Ratings as of
3/30/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 5 hold ratings
  • 0 sell ratings
Ratings as of
6/28/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
9/26/2022
  • 0 strong buy ratings
  • 6 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
12/25/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
2/23/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
3/25/2023

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 4 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/23/2023JPMorgan Chase & Co.Boost TargetNeutral$42.00 ➝ $48.00Low
2/23/2023Needham & Company LLCLower TargetBuy$58.00 ➝ $57.00Low
2/23/2023CitigroupBoost TargetBuy$57.00 ➝ $59.00Low
2/22/2023William BlairReiterated RatingOutperformLow
12/28/2022StephensLower TargetOverweight$69.00 ➝ $68.00Low
12/22/2022MizuhoInitiated CoverageNeutral$48.00Low
12/19/2022JPMorgan Chase & Co.UpgradeUnderweight ➝ Neutral$48.00 ➝ $42.00Low
12/12/2022Wells Fargo & CompanyLower TargetEqual Weight$56.00 ➝ $44.00Low
12/12/2022CitigroupUpgradeNeutral ➝ Buy$57.00Low
11/3/2022JPMorgan Chase & Co.Lower TargetUnderweight$52.00 ➝ $48.00Low
11/3/2022Piper SandlerBoost TargetNeutral$55.00 ➝ $60.00Low
11/3/2022Needham & Company LLCLower TargetBuy$66.00 ➝ $65.00Low
10/13/2022StephensInitiated CoverageOverweight$69.00Low
10/5/2022CitigroupBoost Target$54.00 ➝ $57.00Low
10/4/2022Needham & Company LLCInitiated CoverageBuy$66.00Low
8/4/2022CitigroupBoost Target$49.00 ➝ $54.00Low
7/12/2022Stifel NicolausUpgradeHold ➝ Buy$40.00 ➝ $60.00N/A
5/17/2022CitigroupLower TargetNeutral$58.00 ➝ $43.00N/A
4/18/2022BTIG ResearchBoost Target$61.00 ➝ $66.00Medium
2/23/2022CitigroupBoost TargetNeutral$49.00 ➝ $55.00High
2/3/2022William BlairUpgradeMarket Perform ➝ OutperformMedium
1/19/2022Wells Fargo & CompanyUpgradeUnderweight ➝ Equal Weight$56.00Low
1/18/2022BTIG ResearchUpgradeNeutral ➝ Buy$61.00High
1/7/2022William BlairReiterated RatingMarket PerformHigh
11/5/2021Jefferies Financial GroupBoost TargetHold$54.00 ➝ $60.00Low
11/5/2021Piper SandlerBoost TargetNeutral$45.00 ➝ $55.00High
11/3/2021StephensUpgradeEqual Weight ➝ Overweight$60.00 ➝ $68.00High
10/14/2021JPMorgan Chase & Co.Lower TargetUnderweight$50.00 ➝ $40.00Low
8/6/2021StephensLower TargetEqual Weight$70.00 ➝ $60.00High
8/6/2021Piper SandlerLower TargetNeutral$80.00 ➝ $45.00High
7/28/2021CitigroupLower TargetNeutral$94.00 ➝ $52.00Medium
7/26/2021StephensDowngradeOverweight ➝ Equal Weight$70.00Low
7/20/2021Wells Fargo & CompanyDowngradeEqual Weight ➝ Underweight$41.00High
7/14/2021OppenheimerDowngradeOutperform ➝ Market Perform$105.00Medium
7/14/2021William BlairDowngradeOutperform ➝ Market Perform$34.00High
5/6/2021OppenheimerBoost Target$100.00 ➝ $105.00High
4/8/2021OppenheimerUpgradeMarket Perform ➝ Outperform$93.00 ➝ $100.00High
1/29/2021Piper SandlerDowngradeOverweight ➝ Neutral$70.00 ➝ $80.00Low
12/16/2020Smith Barney CitigroupUpgradeSell ➝ Neutral$50.00 ➝ $72.00Medium
12/8/2020OppenheimerInitiated CoverageMarket Perform$73.00High
11/17/2020Wells Fargo & CompanyUpgradeUnderweight ➝ Equal Weight$68.00Medium
11/6/2020Piper SandlerBoost TargetOverweight$60.00 ➝ $70.00Low
10/8/2020JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight$50.00Low
8/7/2020Piper SandlerBoost TargetPositive ➝ Overweight$50.00 ➝ $60.00High
6/15/2020Jefferies Financial GroupInitiated CoverageHold$44.00Medium
5/8/2020Stifel NicolausLower TargetHold$55.00 ➝ $45.00Low
5/8/2020Piper SandlerLower TargetOverweight$62.00 ➝ $50.00Low
5/5/2020JPMorgan Chase & Co.Lower TargetNeutral$55.00 ➝ $40.00High
4/9/2020Piper SandlerReiterated RatingBuyN/A
4/8/2020Wells Fargo & CompanyLower TargetUnderweight$53.00 ➝ $34.00High
3/27/2020CitigroupLower TargetSell$40.00 ➝ $36.00High
3/23/2020StephensLower TargetOverweight$69.00 ➝ $44.00High
3/4/2020CitigroupInitiated CoverageSell$40.00Medium
2/28/2020Stifel NicolausLower TargetHold$59.00 ➝ $55.00High
2/28/2020Wells Fargo & CompanyLower TargetUnderweight$58.00 ➝ $53.00High
2/28/2020StephensLower TargetOverweight$80.00 ➝ $69.00High
2/28/2020JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$65.00 ➝ $55.00High
1/6/2020Berenberg BankUpgradeHold ➝ Buy$60.00 ➝ $65.00N/A
12/20/2019JPMorgan Chase & Co.Lower TargetOverweight$90.00 ➝ $65.00Medium
12/12/2019Wells Fargo & CompanyDowngradeOverweight ➝ Underweight$58.00High
10/30/2019BTIG ResearchReiterated RatingHoldLow
10/10/2019JPMorgan Chase & Co.Set TargetBuy$90.00Low
9/30/2019Bank of AmericaDowngradeBuy ➝ Underperform$67.00High
8/26/2019JPMorgan Chase & Co.Set TargetBuy$90.00Low
8/14/2019JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$26.00Low
8/13/2019SVB LeerinkReiterated RatingOutperform ➝ Market Perform$25.00 ➝ $22.00High
8/11/2019BTIG ResearchReiterated RatingHoldHigh
8/8/2019CowenDowngradeOutperform ➝ Market Perform$25.00 ➝ $27.00Low
5/22/2019BTIG ResearchReiterated RatingNeutral ➝ HoldLow
5/10/2019BTIG ResearchReiterated RatingHoldLow
5/9/2019BMO Capital MarketsBoost TargetMarket Perform$66.00 ➝ $71.00Medium
3/20/2019Wells Fargo & CompanyReiterated RatingBuyMedium
3/11/2019GuggenheimInitiated CoverageBuy ➝ Buy$21.00High
3/11/2019Bank of AmericaInitiated CoverageBuyHigh
3/11/2019SVB LeerinkInitiated CoverageOutperform$20.00High
3/11/2019CowenInitiated CoverageOutperform$20.00Medium
3/11/2019JPMorgan Chase & Co.Initiated CoverageOverweight ➝ Overweight$16.00Medium
3/8/2019BTIG ResearchInitiated CoverageNeutral ➝ Neutral$66.02Low
2/28/2019Stifel NicolausBoost TargetHold ➝ Positive$58.00 ➝ $68.00High
2/28/2019StephensBoost TargetOverweight$70.00 ➝ $80.00High
2/28/2019Piper Jaffray CompaniesReiterated RatingOverweight$80.00High
9/10/2018StephensBoost TargetOverweight$57.00 ➝ $70.00Medium
9/5/2018BMO Capital MarketsBoost TargetMarket Perform ➝ Market Perform$59.00 ➝ $68.00Medium
8/31/2018Piper Jaffray CompaniesBoost TargetOverweight$73.00Low
8/30/2018Berenberg BankInitiated CoverageHold ➝ Hold$57.00Medium
8/30/2018Wells Fargo & CompanyBoost TargetOutperform$50.00 ➝ $74.00High
8/30/2018BMO Capital MarketsBoost TargetMarket Perform ➝ Market Perform$59.00 ➝ $62.00High
8/29/2018JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$42.00 ➝ $75.00High
8/29/2018StephensReiterated RatingOverweight$57.00High
8/3/2018Piper Jaffray CompaniesBoost TargetOverweight$46.00High
8/3/2018Stifel NicolausBoost TargetHold ➝ Hold$32.00 ➝ $35.00High
7/10/2018BMO Capital MarketsDowngradeOutperform ➝ Market Perform$42.00High
6/21/2018JPMorgan Chase & Co.DowngradeOverweight ➝ NeutralHigh
6/1/2018BMO Capital MarketsBoost TargetOutperform ➝ Outperform$40.00 ➝ $42.00Medium
4/13/2018Stifel NicolausDowngradeBuy ➝ Hold$39.00 ➝ $32.00High
(Data available from 3/26/2018 forward)

News Sentiment Rating

1.12 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 5 very positive mentions
  • 16 positive mentions
  • 5 negative mentions
  • 1 very negative mentions
Mentions as of
8/28/2022
  • 7 very positive mentions
  • 16 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/27/2022
  • 4 very positive mentions
  • 14 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/27/2022
  • 4 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
11/26/2022
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/26/2022
  • 7 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/25/2023
  • 10 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
2/24/2023
  • 11 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/26/2023

Current Sentiment

  • 11 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Glaukos logo
Glaukos Corp. is an ophthalmic medical technology and pharmaceutical company, which focuses on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. It engages in development and commercialization of therapies across several end markets within ophthalmology. The company was founded by Olav B. Bergheim, Morteza Gharib, and Richard Hill on July 14, 1998 and is headquartered in San Clemente, CA.
Read More

Today's Range

Now: $49.35
Low: $47.80
High: $49.58

50 Day Range

MA: $49.00
Low: $45.25
High: $52.48

52 Week Range

Now: $49.35
Low: $33.33
High: $64.49

Volume

289,068 shs

Average Volume

505,510 shs

Market Capitalization

$2.36 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.24

Frequently Asked Questions

What sell-side analysts currently cover shares of Glaukos?

The following sell-side analysts have issued stock ratings on Glaukos in the last year: BTIG Research, Citigroup Inc., JPMorgan Chase & Co., Mizuho, Needham & Company LLC, Piper Sandler, Stephens, Stifel Nicolaus, StockNews.com, Wells Fargo & Company, and William Blair.
View the latest analyst ratings for GKOS.

What is the current price target for Glaukos?

9 Wall Street analysts have set twelve-month price targets for Glaukos in the last year. Their average twelve-month price target is $56.67, suggesting a possible upside of 14.8%. Stephens has the highest price target set, predicting GKOS will reach $68.00 in the next twelve months. Wells Fargo & Company has the lowest price target set, forecasting a price of $44.00 for Glaukos in the next year.
View the latest price targets for GKOS.

What is the current consensus analyst rating for Glaukos?

Glaukos currently has 4 hold ratings and 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe GKOS will outperform the market and that investors should add to their positions of Glaukos.
View the latest ratings for GKOS.

What other companies compete with Glaukos?

Other companies that are similar to Glaukos include Tandem Diabetes Care, NuVasive, Axonics, AtriCure and Alphatec. Learn More about companies similar to Glaukos.

How do I contact Glaukos' investor relations team?

Glaukos' physical mailing address is 229 AVENIDA FABRICANTE, SAN CLEMENTE CA, 92672. The medical instruments supplier's listed phone number is (949) 367-9600 and its investor relations email address is [email protected] The official website for Glaukos is www.glaukos.com. Learn More about contacing Glaukos investor relations.